Pilot Study of Hyperfractionated Dosing of Lutetium‐177–Labeled Antiprostate‐Specific Membrane Antigen Monoclonal Antibody J591 ((177)Lu‐J591) for Metastatic Castration‐Resistant Prostate Cancer

LESSONS LEARNED: Hyperfractionation of lutetium‐177 ((177)Lu)‐J591 for patients with metastatic castration‐resistant prostate cancer did not appear to have any additional advantage over the single dose (177)Lu‐J591 or fractionated two‐dose (177)Lu‐J591 therapy. Definite conclusions were challenging...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Oncologist
Hauptverfasser: Niaz, Muhammad Junaid, Batra, Jaspreet S., Walsh, Ryan D., Ramirez‐Fort, Marigdalia K., Vallabhajosula, Shankar, Jhanwar, Yuliya S., Molina, Ana M., Nanus, David M., Osborne, Joseph R., Bander, Neil H., Tagawa, Scott T.
Format: Artigo
Sprache:Inglês
Veröffentlicht: John Wiley & Sons, Inc. 2020
Schlagworte:
Clinical Trial Results
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7288642/
https://ncbi.nlm.nih.gov/pubmed/31999003
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2020-0028
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge